Avant TP10 First "Males-Only" Heart Drug?: Phase III Awaits Partner
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Avant Immunotherapeutics will pursue a males-only indication for its TP10 complement inhibitor coronary agent in a Phase III trial after a second Phase II study has confirmed a lack of efficacy in women.